Olr390 inhibitors represent a specific class of chemical compounds that interact with the Olr390 protein, a member of the olfactory receptor family. These receptors are G protein-coupled receptors (GPCRs) found primarily in the olfactory epithelium, responsible for detecting odorants and initiating olfactory signal transduction. Olr390, like other olfactory receptors, binds to specific ligands-often volatile organic compounds-triggering a cascade of intracellular events that ultimately result in the perception of smell. Inhibitors of Olr390 can modulate this process by preventing the receptor from binding to its natural ligands or by stabilizing the receptor in a conformation that is less likely to interact with these molecules. This inhibitory action on Olr390 can provide insights into the structural and functional characteristics of olfactory receptors, offering a means to explore the nuances of olfactory signal transduction.
From a chemical perspective, Olr390 inhibitors are typically characterized by their ability to interact with the binding sites of the receptor with high specificity. These inhibitors may be small organic molecules or peptides, each designed to fit precisely within the receptor's binding pocket. The structure-activity relationship (SAR) of these inhibitors is crucial for understanding how alterations in chemical structure can enhance or reduce their affinity for Olr390. The design and synthesis of Olr390 inhibitors often involve extensive computational modeling and biochemical assays to optimize their binding characteristics. By studying these inhibitors, researchers can gain valuable information on the conformational changes in Olr390 upon ligand binding, the nature of the receptor's interaction with various molecules, and the broader implications for GPCR function and olfactory signal processing.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
BCR-ABL tyrosine kinase inhibitor, potentially effective against chronic myeloid leukemia. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
EGFR inhibitor, may block signaling pathways involved in cell proliferation. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
RAF kinase inhibitor, could disrupt cell signaling and tumor growth. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Src family kinase inhibitor. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Multi-targeted receptor tyrosine kinase inhibitor, potentially affects cell proliferation and angiogenesis. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $94.00 $208.00 | 1 | |
MET, VEGFR2, and RET inhibitor, could impact tumor growth and metastasis. | ||||||
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | $182.00 $661.00 $1690.00 | 3 | |
Multi-targeted tyrosine kinase inhibitor, may affect thyroid cancer progression. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
CDK4/6 inhibitor, potentially halts cell cycle in hormone receptor-positive breast cancer. | ||||||
BAY 80-6946 | 1032568-63-0 | sc-503264 | 5 mg | $562.00 | ||
PI3K inhibitor, could inhibit signaling pathways in B-cell malignancies. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Bruton's tyrosine kinase inhibitor, designed to affect cell signaling in certain blood cancers. | ||||||